Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte (INCY) PT Raised to $87 at RBC Capital
July 30, 2019 3:18 PM EDTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Sector Perform rating.
... MoreIncyte (INCY) Tops Q2 EPS by 27c, Raises Guidance
July 30, 2019 7:06 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $0.75, $0.27 better than the analyst estimate of $0.48. Revenue for the quarter came in at $510 million versus the consensus estimate of $496.4 million.
Guidance:
The... More
